Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
2.590
-0.070 (-2.63%)
At close: Aug 24, 2026, 4:00 PM EDT
2.623
+0.033 (1.25%)
After-hours: Aug 24, 2026, 7:30 PM EDT
Nkarta Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
106
Market Cap
185.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Codexis | 77.68M |
| Caribou Biosciences | 10.04M |
| Armata Pharmaceuticals | 5.54M |
| Korro Bio | 2.38M |
| Humacyte | 2.12M |
| Oramed Pharmaceuticals | 2.00M |
NKTX News
- 8 days ago - Nkarta price target lowered to $10 from $11 at Stifel - TheFly
- 13 days ago - Nkarta price target lowered to $14 from $16 at H.C. Wainwright - TheFly
- 14 days ago - Nkarta reports Q2 EPS (54c), consensus (36c) - TheFly
- 14 days ago - Nkarta Earnings release: Q2 2026 - Filings
- 14 days ago - Nkarta Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development - GlobeNewsWire
- 7 weeks ago - Nkarta Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Transcripts
- 2 months ago - Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire